CardioDynamics Announces Fourth Quarter and Fiscal Year 2007 Conference Call and Webcast

SAN DIEGO, Jan. 24 CardioDynamics(Nasdaq: CDIC), the innovator and leader of Impedance Cardiography (ICG)technology, announced that it has scheduled its quarterly conference call andInternet webcast for Thursday, February 7, 2008, at 4:30 p.m. EDT to discussthe Company's financial results for fourth quarter and fiscal year 2007. Thecall will be hosted by CardioDynamics' Chief Executive Officer, Michael Perry,and Chief Financial Officer, Steve Loomis. A press release announcing fourthquarter and fiscal year 2007 results will be available after close of marketon February 7, 2008.

Conference Call and Webcast Information:

To access the conference call, dial 800-346-7359 (Code 7784).International participants can call 973-528-0008 (Code 7784). A replay of thecall will be available for 30 days following the call at 800-332-6854 (Code7784). The international replay number is 973-528-0005 (Code 7784). TheInternet webcast can be accessed athttp://phx.corporate-ir.net/playerlink.zhtml?c=86923&s=wm&e=1748762

Any questions regarding this notice should be directed to Rhonda Rhyne at800-778-4825, ext. 1013, or via e-mail, [email protected].

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator andleader of an important medical technology called impedance cardiography (ICG).The Company develops, manufactures and markets noninvasive ICG products. TheCompany's ICG Systems are being used by physicians around the world to helpbattle the number one killer of men and women -- cardiovascular disease.Partners include GE Healthcare and Philips Medical Systems. For additionalinformation, please refer to the company's Web site at www.cdic.com.COMPANY CONTACT: Rhonda Rhyne, President CardioDynamics 800-778-4825, ext. 1013 [email protected]

SOURCE CardioDynamics

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...